Piper Sandler cuts Connect Biopharma stock price target on launch delay
Piper Sandler reduced its price target for Connect Biopharma (CNTB) to $5.00 from $7.00, citing a delayed launch timeline for rademikibart. The stock is trading at $0.64, down 74% over the past year. The company reported mixed Phase 2 trial results and plans to discuss Phase 3 programs with the FDA. Analysts have mixed price targets, ranging from $4 to $9.
How this was made
The 30-second read
Why it matters
The immediate trading signal is the analyst’s lowered price target driven by a later modeled launch date, which can influence positioning in thinly traded biotech names even without a new clinical failure.
Market read
For CNTB, the PT cut and launch-timing downgrade are a near-term sentiment catalyst, while FDA alignment and Phase 3 design remain the key swing factors.
What to watch
The article notes an FDA baseline FEV1 cutoff question and upcoming FDA discussions in Dec 2026 and Q1 2027; outcomes there could rapidly re-rate the launch timeline assumptions.
Background
Connect Biopharma is developing rademikibart for acute asthma exacerbations and COPD, with mixed Phase 2 Seabreeze STAT results and planned FDA discussions for Phase 3 program design.
Ticker impact
Piper Sandler cut Connect Biopharma’s rademikibart launch timing to 2030 from 2029, lowering its price target to $5 from $7.
Likely pressure as traders price in a later rademikibart launch and weigh mixed Phase 2 asthma versus COPD readouts.
The article’s actionable catalyst is the PT reduction tied to a specific launch-timing change, which typically affects near-term sentiment for pre-revenue biotech. It also flags upcoming FDA discussions that could swing expectations.
Market effects
Reinforces that pre-revenue biotech valuation is highly sensitive to modeled launch timing and FDA Phase 3 design alignment.
Limited, single-name analyst adjustment in US-listed small-cap biotech.
Low, no cross-market policy or sector-wide regulatory action described.
Counterpoint
COPD Phase 2 Seabreeze STAT results are described as strongly positive, which could offset the modeled asthma-driven delay if Phase 3 design is clarified favorably.
Key entities
- companyConnect Biopharma Holdings Ltd
NASDAQ-listed biotech developing rademikibart; subject of the price-target cut and described Phase 2/Phase 3 planning.
- analyst_firmPiper Sandler
Lowered CNTB price target to $5 from $7 while maintaining Overweight, citing launch timing shift to 2030.
- regulatorFood and Drug Administration (FDA)
Upcoming discussions expected to shape Phase 3 program design, including an asthma baseline FEV1 cutoff question.

